Monoclonal Antibody Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
全球單株抗體治療市場在2020年∼2025年間預計將以約13.2％的年複合成長率成長。市場成長的主要原因，是類風濕性關節炎(RA)，發炎性腸道疾病，克隆氏症和癌症等的自體免疫疾病的全球擴大的增加，老年人口的增加導致死亡率上升，造成全球負擔。譬如，美國2020年根據American Cancer Society估計，約有180萬6,950的新癌症病例和估計60萬6,520件癌症死亡，對有效率的治療的需求高漲將刺激全球市場成長。
The Monoclonal Antibody Therapeutics Market studied was anticipated to grow with a CAGR of nearly 13.2%, during the forecast period. The major factors attributing to the growth of the market are a rise in the global prevalence of autoimmune disorders such as (RA) Rheumatoid Arthritis, Inflammatory Bowel Disorder, Crohn's disease and cancers thus leading to the deaths coupled by the increased geriatric population causing global burden. For instance, according to American Cancer Society estimates for the year 2020 in the U.S., about 1,806,950 new cancer cases and 606,520 cancer deaths were estimated which is projected to be continued in future demanding efficient treatment, likely to fuel the demand for the global market. There are few more factors that play a pivotal role in taking the market to the next level such as approval of blockbuster products in recent years and strong pipeline which is expected to fuel the Monoclonal Antibody Therapeutics across the forecast period.
North America is expected to dominate the overall monoclonal antibody therapeutics market throughout the forecast period. The dominance is due to several factors such as rise in geriatric population, increased healthcare expenditure, huge investments by the key players and continuous growth in R&D activities with the rise in application of these therapeutics in the treatment of various disorders such as (PCOS) polycystic ovary syndrome, breast cancers in the United States. For instance, according to the Centers for Disease Control and Prevention CDC report published in 2019, PCOS affects around 6% to 12% representing more than 5 million women of reproductive age and was identified as one of the most common causes of female infertility in the United States fueling the market. Furthermore, the presence of advanced healthcare infrastructure and well-established direct reimbursement policies are also expected to its significant share in the market revenue throughout the forecast period.
The Monoclonal Antibody Therapeutics market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are acquiring the other companies to consolidate their market positions across the globe and while others are launching new products. For instance, Daiichi Sankyo Company in January 2020 added another blockbuster product, ENHERTU (fam-trastuzumab deruxtecan-nxki), in the U.S. to its existing portfolio of monoclonal antibody therapeutics with the accelerated approval by the U.S. Food and Drug Administration (FDA) in December 2019. which is expected to boost the market furthermore throughout the forecast period. Some of the companies which are currently dominating the market are Abbvie Inc, Daiichi Sankyo Company Limited, Johnson & Johnson, Amgen Inc, and UCB Inc.